Differential susceptibility of Dectin-1 isoforms to functional inactivation by neutrophil and fungal proteases

Griffiths, James S., Thompson, Aiysha, Stott, Matthew, Benny, Ankita, Lewis, Natalie A., Taylor, Philip R. ORCID: https://orcid.org/0000-0003-0163-1421, Forton, Julian ORCID: https://orcid.org/0000-0002-0580-0432, Herrick, Sarah, Orr, Selinda J. and McGreal, Eamon P. 2018. Differential susceptibility of Dectin-1 isoforms to functional inactivation by neutrophil and fungal proteases. FASEB Journal 32 (6) , pp. 3385-3397. 10.1096/fj.201701145R

Preview

PDF - Published Version Download (2MB) | Preview

Abstract

Patients with cystic fibrosis (CF) experience chronic or recurrent bacterial and fungal lung infections. Many patients with CF cannot effectively clear Aspergillus from their lungs. This may result in IgE sensitization and the development of allergic bronchopulmonary aspergillosis, or invasive infections, such as Aspergillus bronchitis. Lung disease in patients with CF is associated with neutrophil-dominated inflammation and elevated levels of the serine protease, neutrophil elastase (NE). Various C-type lectin-like receptors (CLRs), including Dectin-1 and Dectin-2, are involved in the immune response to Aspergillus. Here, we show that purified NE cleaves Dectin-1 in an isoform-specific manner. Bronchoalveolar lavage fluid from patients with CF, which contains high NE activity, induces Dectin-1 cleavage. Similarly, filtrate from a protease-producing strain of Aspergillus fumigatus induces isoform-specific cleavage of Dectin-1. Dectin-1 knockout (KO) cells and NE-treated cells demonstrated reduced phagocytosis of zymosan, a fungal cell wall preparation. In addition, NE cleaves 2 other CLRs, Dectin-2 and Mincle, and fungal-induced cytokine production was reduced in Dectin-1 KO cells, Dectin-2 KO cells, and NE-treated cells. Thus, Dectin-1 and Dectin-2 cleavage by NE and/or A. fumigatus–derived proteases results in an aberrant antifungal immune response that likely contributes to disease pathology in patients with CF

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Publisher:	Federation of American Society of Experimental Biology (FASEB)
ISSN:	0892-6638
Funders:	Wellcome Trust 504330, Royal Society
Date of First Compliant Deposit:	16 February 2018
Date of Acceptance:	16 January 2018
Last Modified:	05 Feb 2025 22:31
URI:	https://orca.cardiff.ac.uk/id/eprint/109201

Citation Data

Cited 23 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item